News | Proton Therapy | December 28, 2020

C-RAD Receives Order for Proton Cancer Treatment Centers in the U.S.

C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.

C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.

December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy - Catalyst PT. It is based on the patented Catalyst technology and software as well as the hardware are tailored for the application in this environment.

The Catalyst system is delivered with the complete software suite with modules for Respiratory Gating, Patient Setup and Positioning and Motion Monitoring. The C-RAD SIGRT solution provides a continuous monitoring of the patient during a treatment fraction. The system is delivered with interfaces that allow to interrupt the treatment beam if patient motion is above a clinically defined threshold.

C-RAD Sentinel 4DCT is an easy-to-use, laser-based optical surface scanning system with functionality for four-dimensional CT image reconstruction and gated imaging in a CT room.

"There is a trend within radiation therapy towards high precision treatments. The goal is to improve treatment success and at the same time spare the healthy tissue to minimize side effects." continued Tim Thurn, "To the benefit of the patient, there is a strong motivation to reduce the time for patient setup and positioning. The C-RAD solution is made to support such treatments in a safer and more efficient way."

The total order has a value of 15 MSEK for C-RAD. Delivery and installation for the first center are expected to be concluded during the next three months. The other sites will follow in 2021 and 2022.

For more information: www.c-rad.com

Related Content

icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio
News | Artificial Intelligence | February 23, 2021
February 23, 2021 — icometrix, world leader in imaging...
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
Dr Sahar Saleem placing the mummy in the CT scanner

Dr. Sahar Saleem placing the mummy in the CT scanner. Image courtesy of Sahar Saleem

News | Computed Tomography (CT) | February 22, 2021
February 22, 2021 — Modern medical technology is helping scholars tell a more nuanced story about the fate of an anci
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr
Unhealthy lifestyles, various diseases, stress, and aging can all contribute to an imbalance between the production of ROS and the body's ability to reduce and eliminate them. The resulting excessive levels of ROS cause "oxidative stress".

Unhealthy lifestyles, various diseases, stress, and aging can all contribute to an imbalance between the production of ROS and the body's ability to reduce and eliminate them. The resulting excessive levels of ROS cause "oxidative stress". Graphic courtesy of National Institutes for Quantum and Radiological Science and Technology

News | Magnetic Resonance Imaging (MRI) | February 10, 2021
February 10, 2021 — Oxygen is essential for human life, but within the body, certain biological environmental conditi